Hutchison MediPharma is a pharmaceutical research and development ("R&D") company and aims to bring novel drugs to the global market for the treatment of cancer and auto-immune diseases by using modern drug discovery and development technologies and clinical standards that meet the requirements of ICH guidelines. Hutchison MediPharma has a fully integrated drug discovery and development infrastructure and cutting-edge drug discovery platforms. Over a short period of time, the company has established a rich portfolio of preclinical and clinical candidates and has formed strategic alliances with global leading pharmaceutical giants.
Hutchison MediPharma's competitive advantages lie in the following areas:
- A Western-trained research and development team with expertise and a track record of success in Western and Chinese pharmaceutical development, providing the basis for innovative and high quality research.
- A sustainable tripartite discovery chemistry strategy (based on new botanical drugs, semi-synthetic natural product drugs and synthetic single chemical entity drugs) aimed at creating a diversified portfolio.
- The ability to carry out faster and lower cost human proof of concept studies in China, reducing the risk of failure in subsequent US trials.
- The ability to leverage Hutchison Whampoa Limited's presence in China to negotiate collaborations and obtain in-licensing opportunities, providing access to external drug candidates and proprietary technologies and data, including unique botanical composition samples.